Effects of Glucagon-Like Peptide 1 Receptor Agonists on Mental Health: A Review and Combined Analysis

Conflict of Interest Disclosures: Dr Mizuno reported fellowship grants from Canon Foundation in Europe, consultant fees from WCG Clinical and Signant Health, and manuscript fees from Sumitomo Dainippon Pharma outside the submitted work. Dr Howes reported investigator-initiated research funding from and/or participated in advisory or speaker meetings organized by AbbVie, Alkermes, Angelini, Autifony, Biogen, Boehringer Ingelheim, Delix, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Janssen, Karuna, Lundbeck (where he was previously a part-time employee), Merck, Neumora, Neurocrine, Ontrack/Pangea, Otsuka, Sunovion, Teva, Recordati, Roche, ROVI Biotech, Viatris, and Mylan. Dr McCutcheon reported speaker/consultancy fees from Boehringer Ingelheim, Janssen, Karuna, Lundbeck, Newron, Otsuka, and Viatris and co-directing a company that designs digital resources to support treatment of mental ill health. Dr McGowan reported being a shareholder of Reset Health, receiving research grants from Novo Nordisk, and having received consultant fees for educational/advisory meetings from Novo Nordisk, Lilly, AstraZeneca, Janssen outside the submitted work. Dr Sen Gupta reported speaker fees/educational meeting support from Novo Nordisk outside the submitted work. Dr Ismail reported book royalties from Oxford University Press and her salary being funded in part by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). Dr Pillinger reported receiving speaker/consultancy fees from Boehringer Ingelheim, Recordati, Lundbeck, Otsuka, Janssen, CNX Therapeutics, Sunovion, ROVI Biotech, Schwabe Pharma, and Lecturing Minds Stockholm AB; receiving book royalties from Wiley Blackwell; and co-directing a company that designs digital resources to support treatment of mental illness outside the submitted work. No other disclosures were reported.